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AMP-activated protein kinase (AMPK) is a heterotrimeric
complex, composed of a catalytic subunit (a) and two
regulatory subunits (b and g), which act as a metabolic
sensor to regulate glucose and lipid metabolism. A mu-
tation in the g3 subunit (AMPKg3
R225Q) increases basal
AMPK phosphorylation, while concomitantly reducing
sensitivity to AMP. AMPKg3
R225Q (g3
R225Q) transgenic
mice are protected against dietary-induced triglycer-
ide accumulation and insulin resistance. We deter-
mined whether skeletal muscle–specific expression
of AMPKg3
R225Q prevents metabolic abnormalities in
leptin-deficient ob/ob (ob/ob-g3
R225Q) mice. Glycogen
content was increased, triglyceride content was de-
creased, and diacylglycerol and ceramide content were
unaltered in gastrocnemius muscle from ob/ob-g3
R225Q
mice, whereas glucose tolerance was unaltered. Insulin-
stimulated glucose uptake in extensor digitorum longus
muscle during the euglycemic-hyperinsulinemic clamp
was increased in lean g3
R225Q mice, but not in
ob/ob-g3
R225Q mice. Acetyl-CoA carboxylase phos-
phorylation was increased in gastrocnemius muscle
from g3
R225Q mutant mice independent of adiposity.
Glycogen and triglyceride content were decreased
after leptin treatment (5 days) in ob/ob mice, but not
in ob/ob-g3
R225Q mice. In conclusion, metabolic im-
provements arising from muscle-specific expression
of AMPKg3
R225Q are insufficient to ameliorate insulin re-
sistance and obesity in leptin-deficient mice. Central
defects due to leptin deficiency may override any meta-
bolic benefit conferred by peripheral overexpression of
the AMPKg3
R225Q mutation.
AMP-activated protein kinase (AMPK) is a heterotrimeric
complex, composed of a catalytic subunit (a1 or a2) and
two regulatory subunits (b1 or b2 and g1, g2, or g3), which
acts as a metabolic sensor to regulate glucose and lipid
metabolism (1). AMPK is activated in response to changes
in the intracellular AMP/ATP and ADP/ATP ratios in re-
sponse to cellular stress or nutrient deprivation, changes
in calcium concentration, or alterations in circulating
levels of various hormones including leptin, cytokines,
or adiponectin (2,3). Several lines of evidence highlight
AMPK as an intertissue signal integrator among periph-
eral tissues and the hypothalamus to control whole-body
energy and glucose homeostasis (4–10).
Acute activation of AMPK in peripheral tissues stim-
ulates glucose uptake and lipid oxidation to produce
energy, while turning off energy-consuming processes
including synthesis of glycogen, lipids, and proteins (2).
Pharmacological activation of AMPK in rodents or humans
with insulin resistance or type 2 diabetes increases skeletal
muscle glucose uptake (5,7,11,12) by an insulin-independent
mechanism (13). Although AMPK can form up to 12 unique
heterotrimeric complexes based on the expression of
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different a/b/g subunits, only three complexes (a1/b2/
g1, a2/b2/g1, and a2/b2/g3) are found in human skeletal
muscle (14). Expression profiling of the AMPK g-subunits
in human and rodent skeletal muscle highlights a spe-
cialized role for the g3 isoform in glycolytic fibers (15).
Expression of a naturally occurring mutant (R225Q)
form of the AMPK g3-subunit (16) in COS7 cells increases
basal AMPK phosphorylation, while concomitantly reduc-
ing sensitivity to AMP (17). Moreover, AMPKg3
R225Q
(g3
R225Q) transgenic mice have increased glycogen con-
tent and enhanced mitochondrial biogenesis, and are
protected against dietary-induced triglyceride accumula-
tion and insulin resistance in glycolytic skeletal muscle
(17,18). This phenotype is copied in humans expressing
the rare AMPKg3
R225W mutation, which increases basal
AMPK activity and muscle glycogen content, and de-
creases intramuscular triglyceride levels (19). Thus, lifelong
expression of activated forms of AMPKg3 may prevent
disturbances in glucose and lipid homeostasis that are char-
acteristic of obese people with insulin resistance or type 2
diabetes (20,21).
The hypothalamus is a master regulator of food intake
and energy balance, and coordinates glucose and energy
homeostasis in response to the adipose-derived periph-
eral hormone leptin (22). Hypothalamic AMPK signaling
plays an important role in the regulation of food intake
(4,8,9). Activation of hypothalamic AMPK by counter-
regulatory hormones involved in appetite control as
well as by pharmacological AMPK activators increases
food intake (4,9). Conversely, leptin inhibits hypotha-
lamic AMPK signaling to reduce food intake and body
weight, and increases AMPK signaling in peripheral tis-
sues to promote lipid oxidation (4) and deplete triglycer-
ide stores (23,24). Thus, an appropriate balance between
AMPK signaling in central and peripheral tissues appears
to be important for glucose and energy homeostasis.
Previously, we have provided evidence that muscle-
specific g3
R225Q transgenic mice rendered obese and
hyperleptinemic by a high-fat diet are protected against
excessive intramuscular triglyceride accumulation and
the development of insulin resistance, presumably due
to increased AMPK activation and lipid oxidation in skel-
etal muscle (17). This raises the question of whether
AMPK activation can improve defects in insulin action
and metabolism arising from severe obesity from either
leptin deficiency or impaired leptin signaling. For exam-
ple, in severely obese diabetic leptin receptor-deficient
db/db mice, GLUT4 overexpression can improve glucose
tolerance (25) as well as skeletal muscle insulin sensitiv-
ity (26). Furthermore, AMPK activation by AICAR treat-
ment improves glucose homeostasis in rodents (5,7).
Given the important role of leptin on energy balance,
we determined whether glucose and energy homeosta-
sis are improved by skeletal muscle overexpression of
the mutant AMPKg3
R225Q subunit in leptin-deficient
ob/ob mice and whether the effects of AMPK are leptin-
dependent.
RESEARCH DESIGN AND METHODS
Reagents
Reagents were purchased from Sigma-Aldrich (St. Louis,
MO), unless otherwise stated.
Animals
Wild-type (WT) and skeletal muscle–specific g3
R225Q
transgenic mice were generated as described previously
(17). The transgenic g3
R225Q mutant mice were crossed
with heterozygous ob/+ mice to generate ob/+-g3
R225Q
mice. These ob/+-g3
R225Q mice were bred with ob/+ mice
to generate the four mouse models studied in this report:
lean WT, lean g3
R225Q, ob/ob-WT (ob/ob), and ob/ob-
g3
R225Q mice. The ob/+ mice (on a C57BL/6J background)
were purchased from Charles River Germany. ob/ob mice
are obese and insulin-resistant because of a mutation in
the hormone leptin; the leptin receptor is, however, intact
in ob/ob mice. All the animal experiments were approved
by the regional ethical committee on animal research
Stockholm North, Sweden. Animals had free access to
water and standard rodent chow (Lantmännen, Stock-
holm, Sweden), and were maintained in a temperature-
and light-controlled (12-h light/dark cycle) environment.
Animals were cared for in accordance with regulations for
the protection of laboratory animals. Female and male
mice were studied at 12–16 weeks of age.
Glycogen and Triglyceride Determination
Mice fasted for 4 h were anesthetized with Avertin (2,2,2-
tribromoethanol 99% and tertiary amyl alcohol [1:1 w/v],
500 mg/kg body weight) and gastrocnemius muscle and
liver were removed, cleaned of fat and blood, and quickly
frozen in liquid nitrogen. Glycogen content was deter-
mined fluorometrically on HCl extracts as described
previously (17). Triglyceride content was determined us-
ing a triglyceride/glycerol blanking kit (Roche Diagnostics
Scandinavia, Bromma, Sweden) using Seronorm Lipid as
a standard (17).
Intraperitoneal Glucose Tolerance Test
Animals were fasted for 4 h, and baseline glucose levels
were measured using a OneTouch Ultra glucose meter
(LifeScan, Milpitas, CA). Blood samples were collected
from the tip of the tail. Glucose (1 g/kg) was injected
intraperitoneally, and blood glucose levels were measured
at 15, 30, 60, and 120 min after the injection. Blood was
collected at baseline and 15 min after the glucose
injection to determine insulin levels. Plasma insulin
concentration was determined using an Ultra Sensitive
Insulin ELISA Kit (Crystal Chem, Downers Grove, IL).
Tissue-Specific Glucose Uptake in Conscious Mice
The jugular vein was catheterized 5–7 days prior to the clamp
under isoflurane anesthesia. On the day of experiment,
animals were fasted for 4 h. Euglycemic-hyperinsulinemic
clamps were performed on conscious lean WT and g3
R225Q
mice (10 mU insulin/kg/min) and ob/ob and ob/ob-g3
R225Q
mice (75 mU insulin/kg/min) and insulin-stimulated glu-
cose uptake in glycolytic extensor digitorum longus (EDL)
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and gastrocnemius muscles was determined using 2-deoxy-
D-[1-14C]-glucose (PerkinElmer, Waltham, MA) as a tracer
(27). Results are reported in nanograms of glucose per
milligram per minute.
Lipid Oxidation in Isolated Skeletal Muscle
Palmitate oxidation in isolated EDL muscle was analyzed as
described previously (28). EDL muscles were incubated in
a Krebs-Henseleit buffer. After recovery, muscles were in-
cubated for 2 h in 3H-palmitate (PerkinElmer). Palmitate
oxidation was determined by analyzing the 3H-labeled water
content using liquid scintillation counting. Results are
reported in picomoles per milligram per minute.
Mitochondrial Respiration
Mitochondrial respiration in freshly isolated EDL mus-
cle was determined using high-resolution respirometry
(Oxygraph-2k; Oroboros Instruments, Innsbruck, Austria)
as described previously (29,30). EDL muscles were dis-
sected out, and fibers were gently separated under a micro-
scope. Following saponin permeabilization in ice-cold
relaxing and biopsy preservation solution, tissues were
equilibrated in ice-cold mitochondrial respiration medium
(MiRO5) and 1–2 mg of tissue was added to the respirom-
etry chamber containing MiRO5. Leak respiration was
measured by adding malate and pyruvate in the absence
of ADP. Thereafter, ADP was added to measure oxidative
phosphorylation. Respiration through complex I (C I) was
measured by the addition of glutamate followed by the addi-
tion of succinate to measure C I+II respiration. Maximum flux
through the electron transfer system (ETS) was measured
by the addition of exogenous uncoupler carbonylcyanide-4-
(trifluoromethoxy)-phenyl-hydrazone (ETS I+II). Rotenone
was used to inhibit electron transport through C I (ETS II).
Absolute oxygen flux is expressed relative to tissue wet
weight per second (picomoles of O2 per milligram per
second).
In Vivo Leptin Treatment
Mice were acclimatized in individual cages for a period
of 2–3 days. They were injected with either saline or leptin
(1 mg/kg, reconstituted in saline solution from PeproTech,
Rocky Hill, NJ) at 1600 h for a period of 5 days. Food
consumption and body weights were recorded daily. On
the sixth day, after a 4-h fast, blood glucose level was de-
termined, and the gastrocnemius muscle was dissected and
immediately frozen for determination of triglyceride, gly-
cogen, diacylglycerol (DAG), and ceramide content, and
Western blot analysis.
Body Composition Analysis
Body composition (lean and fat mass) before and after
saline and leptin treatment was determined in conscious
mice using quantitative magnetic resonance imaging
(EchoMRI, Houston, TX).
DAG and Ceramide Content
DAG and ceramide content were determined in gastroc-
nemius muscle from 4-h fasted mice by conversion of
DAG and ceramides to phosphorylation products by
externally added DAG kinase from Escherichia coli (Enzo
Life Sciences, Farmingdale, NY) in the presence of [g-32P]
ATP as previously described (31).
Circulating Free Fatty Acids
Plasma free fatty acids were determined by a commercially
available kit (Wako Chemicals, Dusseldorf, Germany) in
ob/ob and ob/ob-g3
R225Q mice fasted for 4 h.
Western Blot Analysis
Gastrocnemius muscle was homogenized in ice-cold
homogenization buffer (NaCl 137 mmol/L, KCl 2.7
mmol/L, MgCl2 1 mmol/L, Na4O7P2 5 mmol/L, NaF 10
mmol/L, Triton X-100 1%, glycerol 10%, Tris pH 7.8,
20 mmol/L, EDTA 1 mmol/L, phenylmethylsulfonyl fluo-
ride 0.2 mmol/L, Na3VO4 0.5 mmol/L, and protease inhib-
itor cocktail 31) (Calbiochem; Merck Millipore, Billerica,
MA) using the TissueLyser (Qiagen, Hamburg, Germany).
Protein content in the supernatant was determined us-
ing the Pierce BCA protein assay kit (Thermo Scientific,
Rockford, IL). Proteins were separated on a 4–12% Cri-
terion XT Bis-Tris Precast Gel (Bio-Rad, Hercules, CA)
and transferred to nitrocellulose membrane (100 V, 80
min), then blocked in Tris-buffered saline with 0.02%
Tween-20 containing 7.5% nonfat dry milk for 1 h at
room temperature. Membranes were incubated with pri-
mary antibodies overnight at 4°C. MitoProfile total oxi-
dative phosphorylation antibody cocktail was from
Abcam (Cambridge, U.K.). Abundance of the following
complex markers was determined; C I, NADH dehydro-
genase (ubiquinone) 1 b subcomplex 8 (NDUFB8); C II,
succinate dehydrogenase complex, subunit B, iron sulfur
(SDHB); C III, ubiquinol cytochrome c reductase core pro-
tein 2 (UQCRC2); C IV, cytochrome c oxidase I, mitochon-
drial (MTCO1); and C V, ATP synthase, H+ transporting,
mitochondrial F1 complex, a subunit 1 (ATP5A). GLUT4
antibody was from Millipore (Temecula, CA). Phospho-
AMPKaThr172, AMPKa, phospho-acetyl-CoA carboxylase
(ACC) aSer79/bSer212, and ACCa/b antibodies were from
Cell Signaling Technology (Danvers, MA). Phospho-
ACCbSer219/221 and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). The AMPKg3 antibody
was a gift from Dr. Grahame Hardie (University of Dundee,
Dundee, U.K.). Membranes were incubated with appropri-
ate secondary antibody conjugated with horseradish per-
oxidase (Bio-Rad). The immunoreactive proteins were
detected by enhanced chemiluminescence (Amersham,
Arlington Heights, IL) and quantified by calibrated densitom-
etry using Quantity One image analysis software (Bio-Rad).
GAPDH was used as a loading control.
Statistics
Statistical analysis was performed by unpaired two-tailed
Student t test or two-way ANOVA, where applicable. The
g3
R225Q mice were compared with WT mice, and the
ob/ob-g3
R225Q mice were compared with the ob/ob, unless
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otherwise stated. The effect of leptin treatment was com-
pared with saline treatment in the lean and obese mouse
models. Results were considered statistically significant at
P , 0.05.
RESULTS
Glycogen Content in Skeletal Muscle
Glycogen content was determined in the gastrocnemius
muscle from 4-h fasted WT, lean g3
R225Q transgenic,
ob/ob, and ob/ob-g3
R225Q transgenic mice. As previously
reported (17), the AMPKg3
R225Q mutation increased gly-
cogen content in lean mice (Fig. 1). WT and ob/ob mice
have similar levels of glycogen content in the gastrocne-
mius muscle. Consistent with the lean g3
R225Q transgenic
mice, glycogen content in the gastrocnemius muscle was
increased in ob/ob-g3
R225Q transgenic mice compared with
ob/ob mice (Fig. 1).
Glucose Tolerance in ob/ob-g3
R225Q Transgenic Mice
Glucose tolerance was similar between ob/ob and ob/ob-
g3
R225Q transgenic mice (Fig. 2A), consistent with our
previously observation that glucose tolerance is unaltered
in lean WT and g3
R225Q transgenic mice (17). Plasma in-
sulin concentrations determined at baseline and 15 min
after the glucose injection were similar between the ob/ob
and ob/ob-g3
R225Q transgenic mice (Fig. 2B).
In Vivo Insulin-Stimulated Glucose Uptake in Skeletal
Muscle
We performed a euglycemic-hyperinsulinemic clamp to
assess in vivo glucose uptake in EDL and gastrocnemius
muscles. Lean WT and g3
R225Q transgenic mice were clamped
using an insulin infusion of 10 mU/kg/min (baseline plasma
insulin levels were 0.5 6 0.1 and 0.6 60.2 ng/mL, respec-
tively, in WT and g3
R225Q mice, and levels achieved during
the euglycemic-hyperinsulinemic clamp were 9.4 6 0.9
and 11.3 6 1.2 ng/mL, respectively, in WT and g3
R225Q
mice (n = 6–9). ob/ob and ob/ob-g3
R225Q transgenic mice
were clamped using an insulin infusion of 75 mU/kg/min
because of their extreme insulin-resistant state (baseline
plasma insulin levels in ob/ob and ob/ob-g3
R225Q mice
were 15.1 6 5.6 and 9.3 61.6 ng/mL, respectively; levels
achieved in ob/ob and ob/ob-g3
R225Q mice during the
euglycemic-hyperinsulinemic clamp were 281.5 6 60.3
and 338.1 6 17.9 ng/mL, respectively; n = 4). The body
weight of lean mice (WT mice 31.6 6 0.8 g; g3
R225Q mice
32.4 6 1.1 g; n = 10–12) and ob/ob mice (ob/ob 43.6 6
1.3 g; ob/ob-g3
R225Q 41.3 6 1.7 g; n = 6–9) without or
with the g3
R225Q transgene was unaltered. Four-hour
fasted plasma glucose levels were similar between WT
and g3
R225Q mice (8.4 6 0.4 and 9.8 6 0.6 mmol/L, re-
spectively; n = 10–12) and ob/ob and ob/ob-g3
R225Q mice
(9.3 6 0.7 and 11.4 6 1.8 mmol/L, respectively; n = 6–9).
Figure 1—Effect of the AMPKg3
R225Q mutation on skeletal muscle
glycogen content. Glycogen content was measured in the gastroc-
nemius muscle from 4-h–fasted mice in WT (n = 7), g3
R225Q (n = 6),
ob/ob (n = 11), and ob/ob-g3
R225Q (n = 5) mice. Results are given as
the mean 6 SEM. *P < 0.05 vs. WT mice; †††P < 0.001 vs. ob/ob
mice.
Figure 2—Effect of the AMPKg3
R225Q mutation on glucose tolerance. A: Intraperitoneal glucose tolerance tests (1 mg/kg glucose) were
performed in 4-h–fasted ob/ob mice (solid line, n = 9) and ob/ob-g3
R225Q transgenic mice (dashed line, n = 15). B: Plasma insulin levels at
baseline (black bars) and 15 min after the glucose injection (white bars) in ob/ob and ob/ob-g3
R225Q mice (n = 9–10). Results are given as the
mean 6 SEM.
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Insulin-stimulated glucose uptake was increased in glyco-
lytic EDL muscle (Fig. 3A), but not in gastrocnemius muscle
(Fig. 3B), from lean g3
R225Q transgenic mice under in vivo
conditions. Conversely, insulin-stimulated glucose uptake
in EDL and gastrocnemius muscles was unchanged be-
tween ob/ob and ob/ob-g3
R225Q transgenic mice (Fig. 3A
and B). Glucose concentration as well as the glucose
infusion rate were similar at the steady state of the
euglycemic-hyperinsulinemic clamp and after the 2-deoxy-D-
[1-14C]-glucose injection in lean (Fig. 3C and D) and ob/ob
mice (Fig. 3E and F).
Lipid Oxidation in Isolated EDL Muscle
We have previously reported the AMPKg3
R225Q mutation
increases oleate oxidation in EDL muscle from high-fat–fed,
but not chow-fed mice (17). Basal palmitate oxidation was
similar in isolated EDL muscle from WT and ob/ob mice
(Fig. 4). There was an effect of the g3
R225Q transgene to
increase palmitate oxidation in EDL muscle from WT and
ob/ob mice (Fig. 4).
Mitochondrial Respiration in Skeletal Muscle
Mitochondrial respiration in freshly dissected EDL mus-
cles was analyzed using high-resolution respirometry.
Figure 3—Glucose uptake in skeletal muscle from lean and obese g3
R225Q transgenic mice. In vivo insulin-stimulated glucose uptake
in EDL (A) and gastrocnemius (B) muscle was assessed in conscious lean (n = 9–11) and obese (n = 6–9) WT and g3
R225Q transgenic
mice during a euglycemic-hyperglycemic clamp. Plasma glucose concentration and glucose infusion rate (GIR) during the euglycemic-
hyperinsulinemic clamp in lean (C and D) and obese (E and F ) WT and g3
R225Q transgenic mice expressing the WT g3 (solid line) or the
g3
R225Q (dashed line) transgene. At time 0 (indicated by the arrow), 2-deoxy-D-[1-14C]glucose was injected. Results are given as the mean6
SEM. *P < 0.05 vs. WT mice.
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The leak respiration, which denotes endogenous uncou-
pling, was similar between the lean and obese non-
transgenic and transgenic mice (Fig. 5A). Mitochondrial
respiration at the level of C I, ETS I+II, and ETS II was
increased in ob/ob versus WT mice (Fig. 5A). The
AMPKg3
R225Q mutation did not alter the mitochondrial
respiration in skeletal muscle from either WT or ob/ob
mice. Protein abundance of markers of mitochondrial
complexes (NDUFB8, SDHB, UQCRC2, MTCO1, and
ATP5A) in gastrocnemius muscle was unaltered between
WT and ob/ob mice with or without the AMPKg3
R225Q
mutation, except for the C II marker UQCRC2, which
was increased in ob/ob mice compared with WT mice
(Fig. 5B–F).
Effects of 5 Days In Vivo Leptin Treatment on Food
Intake, Body Composition, Muscle Biochemistry, and
Signaling
Five-day intraperitoneal leptin treatment reduced food
intake in lean and obese nontransgenic and transgenic
mice, compared with the respective saline-treated mice
(Fig. 6A). Leptin treatment decreased body weight in WT,
ob/ob, and ob/ob-g3
R225Q mice compared with the respec-
tive saline-treated mice (Fig. 6B). In contrast, leptin treat-
ment did not significantly decrease body weight in the
lean g3
R225Q transgenic mice (Fig. 6B).
Body composition was assessed using magnetic reso-
nance imaging. Total fat mass was reduced in leptin-
treated ob/ob and ob/ob-g3
R225Q transgenic mice, compared
with the respective saline-treated mice (Fig. 6C). Lean mass
was unaltered after saline or leptin treatment in the lean
and obese nontransgenic and transgenic mice (Fig. 6D).
Leptin treatment reduced 4-h fasting blood glucose levels
in ob/ob-g3
R225Q transgenic mice, with a similar trend in
ob/ob mice (Fig. 6E).
Gastrocnemius muscle was used for biochemical analysis.
Glycogen content was increased in the saline-treated lean
g3
R225Q transgenic mice, compared with the WT mice (Fig.
7A). Similarly, glycogen content was increased in ob/ob-
g3
R225Q transgenic mice, compared with the ob/ob mice. Gly-
cogen content was not altered in WT and g3
R225Q transgenic
mice after leptin treatment. However, glycogen content was
reduced in ob/obmice compared with saline-treated ob/obmice
after leptin treatment, but not in ob/ob-g3
R225Q transgenic
mice (Fig. 7A). GLUT4 protein abundance was unaltered
in gastrocnemius muscle from lean and ob/ob mice
g3
R225Q transgenic mice (Fig. 7B).
Triglyceride content in gastrocnemius muscle was
unaltered between saline- and leptin-treated WT and
g3
R225Q transgenic mice (Fig. 7C). While triglyceride con-
tent was elevated in ob/ob versus WT mice, the presence
of the AMPKg3
R225Q transgene in the ob/ob mice (ob/ob-
g3
R225Q mice) reduced triglyceride content. Furthermore,
leptin treatment reduced triglyceride content in ob/ob
mice. However, leptin treatment did not further reduce
triglyceride content in gastrocnemius muscle from the
ob/ob-g3
R225Q transgenic mice (Fig. 7C). DAG and cer-
amide content were assessed in gastrocnemius muscle
from saline- and leptin-treated mice. DAG content was in-
creased in ob/ob mice compared with WT mice (Fig. 7D).
DAG content was unaltered in saline- or leptin-treated
g3
R225Q transgenic mice (Fig. 7D). Ceramide content was
unaltered in gastrocnemius muscle from saline- or leptin-
treated WT and ob/ob nontransgenic and transgenic mice
(Fig. 7E). Furthermore, liver triglyceride content was un-
altered between ob/ob and ob/ob-g3
R225Q mice (52.6 6
5.3 and 52.6 6 4.3 mg/g, respectively, for ob/ob and
ob/ob-g3
R225Q mice; n = 8–11). Circulating free fatty acids
were similar between ob/ob and ob/ob-g3
R225Q mice (0.396
0.07 and 0.37 6 0.05 mmol/L, respectively, for ob/ob and
ob/ob-g3
R225Q mice; n = 7).
AMPKaThr172 phosphorylation in gastrocnemius mus-
cle from saline-treated lean and obese nontransgenic and
transgenic mice was similar (Fig. 8A). Skeletal muscle
AMPKaThr172 phosphorylation was increased after the
5-day leptin administration in ob/ob-g3
R225Q transgenic
mice (Fig. 8A). AMPKa and AMPKg3 subunit protein
abundance was increased in lean g3
R225Q transgenic
mice independent of treatment compared with WT mice
(Fig. 8B and C), but not in ob/ob and ob/ob-g3
R225Q trans-
genic mice. ACCaSer79/bSer212 and ACCbSer219/221 phos-
phorylation was increased in gastrocnemius muscle from
lean and ob/ob-g3
R225Q transgenic mice (Fig. 8D and E).
ACCa/b protein abundance was increased in lean g3
R225Q
transgenic mice (Fig. 8F). ACC phosphorylation or abun-
dance was unaltered in leptin-treated lean and obese
nontransgenic and transgenic mice compared with the
respective saline-treated mice.
DISCUSSION
Overexpression of key signaling proteins regulating
energy metabolism in skeletal muscle can improve
Figure 4—Lipid oxidation in skeletal muscle from lean and obese
g3
R225Q transgenic mice. Basal in vitro palmitate oxidation was
measured in EDL muscle from 4-h–fasted lean (n = 7) and obese
(n = 7–11) mice. Results are given as the mean 6 SEM. #P < 0.05
indicates the effect of the g3
R225Q transgene.
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metabolic disturbances associated with insulin resis-
tance. Improvements in glucose homeostasis have been
achieved by overexpression of either GLUT4 or un-
coupling protein 3 in skeletal muscle of mice (25,32).
AMPK activation by AICAR treatment can also improve
glucose homeostasis in rodents (5,7). Here we tested
the hypothesis that expression of a single missense
mutation (R225Q) in the AMPKg3 isoform in skeletal
muscle of ob/ob-g3
R225Q mice improves glucose and
energy homeostasis. We also determined whether lep-
tin treatment would further normalize metabolic dis-
turbances in obese individuals and whether the effects
of AMPK activation on glucose homeostasis are leptin-
dependent.
Impairments in whole-body glucose metabolism in type 2
diabetes patients are mainly attributed to defects in
skeletal muscle glucose uptake and glycogen synthesis
(33). Despite severe insulin resistance, AMPK activation
promotes GLUT4 translocation and increases glucose up-
take directly in skeletal muscle from insulin-resistant type
2 diabetes patients (11). A role for the AMPKg-subunit in
glucose metabolism was first appreciated from studies of
Hampshire pigs expressing a naturally occurring domi-
nant mutation (denoted RN2) in the gene encoding the
AMPKg3-isoform (34). This mutation results in an exces-
sive amount of glycogen storage in glycolytic skeletal
muscle. In vitro studies in COS7 cells reveal that
AMPKg3
R225Q complexes have higher basal AMPK activity
Figure 5—Mitochondrial respiration in skeletal muscle. A: Oxidative phosphorylation and ETS capacity were analyzed in glycolytic EDL
muscle from lean and obese WT (black bars) or AMPK g3
R225Q transgenic (white bars) mice using high-resolution respirometry. WT g3, black
bars, n = 8–10; g3
R225Q, white bars, n = 8–9. Protein abundance of markers of C I (NDUFB8) (B), C II (SDHB) (C ), C III (UQCRC2) (D), C IV
(MTCO1) (E ), and C V (ATP5A) (F ) were determined in gastrocnemius muscle from WT, g3
R225Q, ob/ob, and ob/ob-g3
R225Q mice (n = 5–11).
Results are given as the mean 6 SEM; *P < 0.05 vs. WT mice. AU, arbitrary units; ob, obese; Jo2, absolute oxygen flux.
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and lack AMP dependence (17). Thus, the R225Q muta-
tion is a gain-of-function mutation that abolishes alloste-
ric regulation by AMP/ATP, which thereby increases basal
AMPK activity.
g3
R225Q transgenic mice fed a high-fat diet are pro-
tected against the development of skeletal muscle insu-
lin resistance (17). Here we report that in vivo glucose
uptake in glycolytic skeletal muscle is increased during
a euglycemic-hyperinsulinemic clamp in lean g3
R225Q
transgenic mice. Consistent with our earlier findings in
fat-fed g3
R225Q transgenic mice (17), we found that gly-
cogen content was increased and triglyceride content
was decreased in gastrocnemius muscle from ob/ob-
g3
R225Q transgenic mice. These changes in ob/ob-
g3
R225Q mice indicate that leptin is not required for
AMPK-mediated glycogen synthesis. Moreover, the ef-
fect of the AMPKg3
R225Q mutation on glycogen content is
independent of adiposity, consistent with clinical studies in
obese humans harboring a similar mutation in the
AMPKg3 subunit who have higher skeletal muscle glycogen
content compared with WT carriers (19). However, in con-
trast to our earlier study in fat-fed mice (17), improve-
ments in muscle biochemistry arising from the
AMPKg3
R225Q mutation were insufficient to ameliorate
whole-body insulin resistance in leptin-deficient mice.
Thus, a permissive amount of leptin may be required to
fully confer the AMPKg3
R225Q-dependent improvements in
skeletal muscle insulin sensitivity.
Several molecular mechanisms account for skeletal
muscle glycogen accumulation. Skeletal muscle GLUT4
protein abundance directly influences the rate of insulin-
stimulated glucose uptake and metabolism (35). Moreover,
GLUT4 overexpression prevents insulin resistance (26) and
glucose intolerance (25) in severely obese diabetic leptin
Figure 6—Effect of leptin treatment on food intake and body composition. WT (n = 7–10), g3
R225Q (n = 7–11), ob/ob (n = 6–8), and ob/ob-
g3
R225Q (n = 7–8) mice were treated with saline or leptin (1 mg/kg) for 5 days. A: Food intake was assessed in saline- and leptin-treated
mice. B: The effect of saline or leptin on body weight was assessed over a 5-day treatment period. Changes in body composition (fat mass
[C] and lean mass [D]) were measured by magnetic resonance imaging after 5 days of saline or leptin treatment. E: Four-hour fasting
glucose concentration was determined 16 h after the 5-day saline/leptin treatment period. Saline treatment, black bars; leptin treatment,
white bars. Results are given as the mean 6 SEM. ‡P < 0.05, ‡‡P < 0.01, ‡‡‡P < 0.001 vs. respective saline-treated mice.
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receptor–deficient db/db mice, highlighting the impor-
tance of skeletal muscle glucose transport in maintaining
whole-body glucose homeostasis. Skeletal muscle–specific
overexpression of glycogen synthase increases glycogen
accumulation by an insulin-independent mechanism not
involving glucose transport (36), reinforcing the impor-
tance of glucose metabolism. Despite the profound increase
in glycogen content in chow-fed lean g3
R225Q mice, basal
and insulin-stimulated glucose uptake in isolated skeletal
muscle was similar to WT mice (17). Furthermore, GLUT4
protein abundance was unaltered in gastrocnemius mus-
cle from lean and ob/ob nontransgenic and transgenic mice.
Thus, the increase in glycogen content in g3
R225Q trans-
genic mice is unlikely to arise from constitutive increases in
glucose uptake. Consequently, g3
R225Q mice resemble gly-
cogen synthase transgenic mice, rather than GLUT4
transgenic mice. Glycogen content negatively regulates
both AMPK activity (37) and insulin-stimulated glucose
uptake (38). However, glucose uptake in glycolytic muscle
was increased despite increased glycogen content. Thus,
improvements in glucose uptake may require permissive
levels of leptin, since the AMPKg3
R225Q mutation did not
increase glucose uptake in leptin-deficient ob/ob mice. Al-
ternatively, increased GLUT4 abundance or translocation
may be required to achieve improvements in glucose toler-
ance and insulin sensitivity in individuals with severe obe-
sity due to leptin deficiency.
Although lipids serve as an important fuel source for
skeletal muscle, excessive levels may trigger insulin re-
sistance (39). Strategies to reduce excess triglyceride lev-
els in skeletal muscle improve insulin sensitivity (17,40).
Intramuscular triglyceride content is reduced and insulin
sensitivity is increased in g3
R225Q transgenic mice fed a
high-fat diet concomitant with increased lipid oxidation
(17). Likewise, intramuscular triglyceride content was re-
duced in ob/ob-g3
R225Q transgenic mice, presumably due
to decreased triglyceride synthesis and a modest increase
in lipid oxidation. DAG and ceramide content, intermedi-
ates in lipid metabolism, have been linked to the devel-
opment of insulin resistance in skeletal muscle (41). Here
we confirm that DAG content is increased in gastrocne-
mius muscle from ob/ob mice (42), yet it was unaltered
Figure 7—Effect of leptin treatment on skeletal muscle glycogen and triglyceride content. Skeletal muscle was dissected from 4-h–fasted
WT (n = 6–11), g3
R225Q (n = 8–11), ob/ob (n = 5–7), and ob/ob-g3
R225Q (n = 9–10) mice 16 h after the 5-day saline or leptin (1 mg/kg)
treatment period. Glycogen content (A), GLUT4 protein abundance (B), triglyceride content (C ), DAG content (D), and ceramide content
(E ) were measured in the gastrocnemius muscle. Saline treatment, black bars; leptin treatment, white bars. Results are given as the mean6
SEM. ***P < 0.001 vs. saline-treated WT mice; ††P < 0.01, †††P < 0.001 vs. saline-treated ob/ob mice; ‡P < 0.05, ‡‡‡P < 0.001 vs.
respective saline-treated mice.
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in g3
R225Q transgenic mice. Ceramide content in gastroc-
nemius muscle was similar between transgenic and non-
transgenic WT and ob/ob mice, confirming previous reports
(42,43). However, phosphorylation of ACC, a downstream
target of AMPK (44), was increased in g3
R225Q transgenic
mice. Increased ACC phosphorylation leads to inactivation
of the enzyme, which thereby increases lipid oxidation
and decreases triglyceride levels (45). The increase in ACC
phosphorylation suggests that the cellular energy charge
driven by the AMPK mutation is altered (17), consistent
Figure 8—AMPK and ACC phosphorylation in skeletal muscle. Mice were treated with saline or leptin (1 mg/kg) for 5 days (WT [n = 6–9],
g3
R225Q [n = 6–11], ob/ob [n = 5–6], and ob/ob-g3
R225Q [n = 6–9] mice). Phospho-AMPKaThr172 (pAMPKaThr172) (A), AMPKa (B), AMPKg3
protein abundance (C), phospho-ACCaSer79/bSer212 (pACCaSer79/bSer212) (D), phospho-ACCbSer219/221 (p-ACCbSer219/221) (E ), and ACCa/b
protein abundance (F ) were determined by immunoblot analysis in the gastrocnemius muscle. Saline treatment, black bars; leptin treat-
ment, white bars. Results are given as the mean 6 SEM. ‡P < 0.05 vs. respective saline-treated mice; *P < 0.05, **P < 0.01, ***P < 0.001
vs. WT mice; †P < 0.05, †††P < 0.001 vs. saline-treated ob/ob mice. AU, arbitrary units.
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with increased lipid oxidation in the g3
R225Q transgenic
mice.
Leptin influences AMPK signaling in central and
peripheral tissues. Leptin inhibits AMPK activity in the
brain and reduces food intake (4), while enhancing lipid
metabolism in skeletal muscle (46). Thus, we explored
whether leptin treatment of ob/ob-g3
R225Q transgenic
mice would lead to a further metabolic improvement im-
posed by the AMPKg3
R225Q mutation. The AMPKg3
R225Q
mutation did not alter the body weight response to leptin
treatment in ob/ob mice. Thus, the metabolic differences
observed between the nontransgenic and ob/ob-g3
R225Q
transgenic mice are directly related to the mutation,
rather than to changes in food intake. Leptin treatment
improved the fasting glucose level in ob/ob-g3
R225Q trans-
genic mice, concomitant with a normalization of food in-
take and a reduction in adiposity. Moreover, we found
that skeletal muscle glycogen content was decreased in
leptin-treated ob/ob mice, consistent with the effects of
leptin in decreasing glycogen synthesis in ob/ob mice (47).
However, leptin treatment did not decrease skeletal mus-
cle glycogen content in g3
R225Q transgenic lean and ob/ob
mice, indicating that the AMPKg3
R225Q mutation has
a dominant influence on fuel partitioning within skeletal
muscle, which may be overcome by hyperleptinemia. Al-
though the concentration of leptin used in this study was
sufficient to improve blood glucose and body weight,
higher doses trigger a shift in substrate use such as that
observed in fat-fed g3
R225Q mice (17).
AMPK activation is linked to mitochondrial biogenesis,
providing a mechanism for the increased lipid oxidation
observed in fat-fed g3
R225Q transgenic mice (17). The in-
crease in mitochondrial respiration in ob/ob mice confirms
our previous findings that obesity induces molecular adap-
tations in glycolytic skeletal muscle to enhance mitochon-
drial respiration (48). Nevertheless, these mice are severely
insulin-resistant. Mitochondrial biogenesis is increased in
glycolytic skeletal muscle from g3
R225Q transgenic mice,
concomitant with increased expression of the coactivator
peroxisome proliferator–activated receptor g coactivator-
1a and transcription factors that drive different mitochon-
drial proteins expression (18). However, mitochondrial
respiration is unaltered between WT and g3
R225Q trans-
genic mice (18), as well as ob/ob-g3
R225Q transgenic mice.
The increase in skeletal muscle mitochondrial markers in
g3
R225Q transgenic mice (18) may account for the increase
in lipid oxidation in the g3
R225Q transgenic mice. However,
the regulation of insulin sensitivity is complex and not
entirely coupled to increased skeletal muscle mitochondrial
content. Nevertheless, cultured myotubes from probands
carrying a homologous mutation (AMPKg3
R225W) reinforce
the profound effect of this mutation on glucose uptake and
metabolism, mitochondrial content, and oxidative capacity,
and raise the clinical implications of mutations in the
AMPKg3 subunit (49).
Defective leptin action leads to metabolic abnormalities
associated with obesity. The effects of leptin are partly
mediated via the AMPK pathway in central and peripheral
sites. Here we show that the expression of a mutant
form of the AMPKg3 subunit in glycolytic skeletal muscle
increases glycogen content and decreases intramuscular
triglyceride levels. However, DAG and ceramide content
were unaltered. The triglyceride depletion in ob/ob-g3
R225Q
transgenic mice does not appear to improve glucose utili-
zation and insulin sensitivity in ob/ob-g3
R225Q mice. Thus,
the lack of central leptin signaling may override the
favorable metabolic milieu conferred by peripheral overex-
pression of the AMPKg3
R225Q mutation to improve glucose
and energy homeostasis. Further studies in hypothalamic-
specific AMPK transgenic ob/obmice may clarify the central
role of this protein kinase in the control of glucose and
energy homeostasis in leptin deficiency. Given our find-
ings (Supplementary Table 1), targeting both peripheral
and central AMPK actions may be required to improve
glucose homeostasis.
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